Sarepta Elevidys Safety Concerns - Search News

Order byBest matchMost fresh

News

FDA, Sarepta and Elevidys

FDA allows Sarepta to resume some Elevidys shipments

The company can again ship the Duchenne gene therapy for patients who can still walk, following a one-week pause triggered by safety concerns.

Continue reading

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys

Fierce Pharma · 5h

FDA takes U-turn on Sarepta’s Elevidys, backing Duchenne gene therapy again in ambulatory patients

13hon MSN

Sarepta rises 2%; Barclays downgrades to underweight on liquidity and Elevidys concerns

Sarepta Therapeutics (NASDAQ:SRPT) shares dropped sharply premarket on Monday before paring losses as Barclays revised its ...

Sarepta’s Future Increasingly Uncertain as FDA Eyes New Study for Elevidys

CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results